Literature DB >> 2492599

Effects of leuprolide in the treatment of central precocious puberty.

P A Lee1, J G Page.   

Abstract

Leuprolide acetate (D-Leu6 des-Gly-NH2(10), Pro-ethylamide9), a synthetic non-apeptide analog of naturally occurring gonadotropin releasing hormone, was used to treat 62 children with central precocious puberty. Sex steroid levels (testosterone in boys and estradiol in girls) were suppressed during treatment lasting from 3.5 to 24.9 months. Basal follicle-stimulating hormone values and both luteinizing hormone and follicle-stimulating hormone peak responses to stimulation by luteinizing hormone releasing hormone were also suppressed, although basal luteinizing hormone values did not differ. Linear growth rate and the rate of bone age advancement decreased during leuprolide therapy. Side effects were minimal. The long-term safety of this treatment has not yet been established; however, leuprolide appears to be an effective long-term therapy for central precocious puberty.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2492599     DOI: 10.1016/s0022-3476(89)80806-6

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  7 in total

Review 1.  Drug treatment in precocious puberty.

Authors:  M D Wheeler; D M Styne
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

2.  Final height in central precocious puberty after long term treatment with a slow release GnRH agonist.

Authors:  W Oostdijk; B Rikken; S Schreuder; B Otten; R Odink; C Rouwé; M Jansen; W J Gerver; J Waelkens; S Drop
Journal:  Arch Dis Child       Date:  1996-10       Impact factor: 3.791

3.  Treatment of gonadotropin dependent precocious puberty due to hypothalamic hamartoma with gonadotropin releasing hormone agonist depot.

Authors:  V N de Brito; A C Latronico; I J Arnhold; L S Lo; S Domenice; M C Albano; M C Fragoso; B B Mendonca
Journal:  Arch Dis Child       Date:  1999-03       Impact factor: 3.791

4.  Hypothalamic hamartomas and precocious puberty.

Authors:  M P Colaco; M P Desai; C S Choksi; K N Shah; R U Mehta
Journal:  Indian J Pediatr       Date:  1993 May-Jun       Impact factor: 1.967

Review 5.  Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.

Authors:  G L Plosker; R N Brogden
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546

6.  Treatment with Depot Leuprolide Acetate in Girls with Idiopathic Precocious Puberty: What Parameter should be Used in Deciding on the Initial Dose?

Authors:  Doğuş Vurallı; Ayfer Alikaşifoğlu; İrem İyigün; Dicle Canoruç; Alev Ozon; Nazlı Gönç; Nurgün Kandemir
Journal:  J Clin Res Pediatr Endocrinol       Date:  2019-07-26

7.  Evaluating the Efficacy of Treatment with a GnRH Analogue in Patients with Central Precocious Puberty.

Authors:  H Nur Peltek Kendirci; Sebahat Yılmaz Ağladıoğlu; Veysel N Baş; Aşan Önder; Semra Çetinkaya; Zehra Aycan
Journal:  Int J Endocrinol       Date:  2015-10-13       Impact factor: 3.257

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.